JP2025509088A - Ｎｌｒｐ３の阻害剤 - Google Patents
Ｎｌｒｐ３の阻害剤 Download PDFInfo
- Publication number
- JP2025509088A JP2025509088A JP2024548556A JP2024548556A JP2025509088A JP 2025509088 A JP2025509088 A JP 2025509088A JP 2024548556 A JP2024548556 A JP 2024548556A JP 2024548556 A JP2024548556 A JP 2024548556A JP 2025509088 A JP2025509088 A JP 2025509088A
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound
- mmol
- equiv
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311463P | 2022-02-18 | 2022-02-18 | |
| US63/311,463 | 2022-02-18 | ||
| PCT/US2022/075421 WO2023028534A1 (en) | 2021-08-25 | 2022-08-24 | Inhibitors of nlrp3 |
| USPCT/US2022/075421 | 2022-08-24 | ||
| PCT/US2023/062771 WO2023159148A2 (en) | 2022-02-18 | 2023-02-16 | Inhibitors of nlrp3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025509088A true JP2025509088A (ja) | 2025-04-11 |
| JP2025509088A5 JP2025509088A5 (enExample) | 2026-02-25 |
Family
ID=87579158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024548556A Pending JP2025509088A (ja) | 2022-02-18 | 2023-02-16 | Ｎｌｒｐ３の阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250179078A1 (enExample) |
| EP (1) | EP4479045A4 (enExample) |
| JP (1) | JP2025509088A (enExample) |
| KR (1) | KR20240164495A (enExample) |
| CN (2) | CN118302417A (enExample) |
| AU (1) | AU2023221847A1 (enExample) |
| CA (1) | CA3243870A1 (enExample) |
| CL (1) | CL2024002455A1 (enExample) |
| CO (1) | CO2024011162A2 (enExample) |
| CR (1) | CR20240345A (enExample) |
| IL (1) | IL315027A (enExample) |
| MX (1) | MX2024010092A (enExample) |
| PE (1) | PE20250604A1 (enExample) |
| WO (1) | WO2023159148A2 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022230912A1 (ja) | 2021-04-28 | 2022-11-03 | アステラス製薬株式会社 | 置換トリアジン化合物 |
| JP2024529839A (ja) * | 2021-06-29 | 2024-08-14 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
| WO2023051761A1 (zh) * | 2021-09-30 | 2023-04-06 | 成都奥睿药业有限公司 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
| JP2025524640A (ja) * | 2022-07-14 | 2025-07-30 | エーシー・イミューン・エス・アー | Ｎｌｒｐ３インフラマソーム経路の調節剤としてのピロロトリアジン及びイミダゾトリアジン誘導体 |
| CN120379995A (zh) * | 2022-12-27 | 2025-07-25 | 正大天晴药业集团股份有限公司 | 一种哒嗪稠芳环化合物及其用途 |
| JP2026508178A (ja) | 2023-02-14 | 2026-03-10 | シェンチェン ジョンジー バイオロジカル テクノロジー カンパニー， リミテッド | Ｎｌｒｐ３を阻害する化合物及びその製造方法と応用 |
| TW202535370A (zh) * | 2023-12-14 | 2025-09-16 | 美商默沙東有限責任公司 | 作為nod樣受體蛋白3抑制劑之吲唑衍生物 |
| WO2025133307A1 (en) * | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
| WO2026067767A1 (zh) * | 2024-09-30 | 2026-04-02 | 普罗思特(南京)生物科技有限公司 | 取代的哒嗪衍生物及其应用 |
| WO2026132518A1 (en) | 2024-12-20 | 2026-06-25 | Ac Immune Sa | Heterocyclic compounds modulating the nlrp3 inflammasome pathway |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104583208B (zh) * | 2012-05-16 | 2016-09-28 | 杨森制药公司 | 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物 |
| WO2014007217A1 (ja) * | 2012-07-02 | 2014-01-09 | 大鵬薬品工業株式会社 | イミダゾオキサジン化合物による抗腫瘍効果増強剤 |
| WO2018221433A1 (ja) * | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | ヘテロアリールアミン誘導体 |
| CA3174837A1 (en) * | 2020-04-15 | 2021-10-21 | Daniel Oehlrich | Pyrazolo[1,5-d][1,2,4]triazine-5(4h)-acetamides as inhibitors of the nlrp3 inflammasome pathway |
| JP2024529839A (ja) * | 2021-06-29 | 2024-08-14 | ズーマゲン バイオサイエンシーズ エルティーディー | Ｎｌｒｐ３モジュレーター |
| IL310992A (en) * | 2021-08-25 | 2024-04-01 | Ptc Therapeutics Inc | NLRP3 inhibitors |
| WO2023051761A1 (zh) * | 2021-09-30 | 2023-04-06 | 成都奥睿药业有限公司 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
-
2022
- 2022-08-24 CN CN202280071320.9A patent/CN118302417A/zh active Pending
-
2023
- 2023-02-16 IL IL315027A patent/IL315027A/en unknown
- 2023-02-16 CR CR20240345A patent/CR20240345A/es unknown
- 2023-02-16 CN CN202380034776.2A patent/CN119212699A/zh active Pending
- 2023-02-16 JP JP2024548556A patent/JP2025509088A/ja active Pending
- 2023-02-16 PE PE2024001809A patent/PE20250604A1/es unknown
- 2023-02-16 EP EP23757102.1A patent/EP4479045A4/en active Pending
- 2023-02-16 WO PCT/US2023/062771 patent/WO2023159148A2/en not_active Ceased
- 2023-02-16 US US18/839,229 patent/US20250179078A1/en active Pending
- 2023-02-16 AU AU2023221847A patent/AU2023221847A1/en active Pending
- 2023-02-16 KR KR1020247027203A patent/KR20240164495A/ko active Pending
- 2023-02-16 CA CA3243870A patent/CA3243870A1/en active Pending
-
2024
- 2024-08-15 CL CL2024002455A patent/CL2024002455A1/es unknown
- 2024-08-16 CO CONC2024/0011162A patent/CO2024011162A2/es unknown
- 2024-08-16 MX MX2024010092A patent/MX2024010092A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN119212699A (zh) | 2024-12-27 |
| CO2024011162A2 (es) | 2024-12-09 |
| CA3243870A1 (en) | 2023-08-24 |
| WO2023159148A3 (en) | 2023-10-05 |
| AU2023221847A1 (en) | 2024-09-05 |
| CN118302417A (zh) | 2024-07-05 |
| US20250179078A1 (en) | 2025-06-05 |
| PE20250604A1 (es) | 2025-02-26 |
| WO2023159148A2 (en) | 2023-08-24 |
| MX2024010092A (es) | 2024-12-06 |
| CR20240345A (es) | 2024-09-16 |
| IL315027A (en) | 2024-10-01 |
| EP4479045A2 (en) | 2024-12-25 |
| EP4479045A4 (en) | 2026-03-04 |
| CL2024002455A1 (es) | 2025-01-17 |
| KR20240164495A (ko) | 2024-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023159148A2 (en) | Inhibitors of nlrp3 | |
| AU2022334474A1 (en) | Inhibitors of nlrp3 | |
| CN101243088B (zh) | p38 MAP激酶抑制剂及使用它的方法 | |
| WO2023028536A1 (en) | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 | |
| JP4015176B2 (ja) | 高血圧症の治療に有用な５，７−ジアミノピラゾロ４，３−ジピリミジン類 | |
| JP2026502905A (ja) | Ｎｌｒｐ３の阻害剤としてのヘテロ環式及びヘテロアリール化合物 | |
| JP2005529909A (ja) | Ｇａｂａ受容体に対するリガンドとしてのイミダゾ−トリアジン誘導体 | |
| JP2020533376A (ja) | ピラゾロピリミジノン化合物およびその使用 | |
| JP2004505086A (ja) | Ｇａｂａ受容体に対するリガンドとしてのイミダゾ−ピラジン誘導体 | |
| AU2010214101A1 (en) | Histamine H3 inverse agonists and antagonists and methods of use thereof | |
| WO2003093273A1 (en) | Imidazo-triazine derivatives as ligands for gaba receptors | |
| JP2004536862A (ja) | Ｇａｂａ受容体のためのリガンドとしてのイミダゾ−トリアジン誘導体 | |
| JP2024545591A (ja) | ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法 | |
| CN111727191A (zh) | 取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其作为磷酸二酯酶抑制剂的用途 | |
| KR20190067788A (ko) | Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 화합물 | |
| JP2003507479A (ja) | Ｇａｂａ受容体リガンドとしてのイミダゾ−トリアジン誘導体 | |
| CA3171441A1 (en) | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as gabaa .alpha_5.receptor modulators | |
| CN108148060A (zh) | 取代的杂环化合物及其衍生物，其药物组合物、制备方法及用途 | |
| JP2009506009A (ja) | ｐ３８ＭＡＰキナーゼ阻害剤及びその使用方法 | |
| US20250051323A1 (en) | BICYCLIC AMINE DERIVATIVES AS GABAA alpha5 RECEPTOR MODULATORS | |
| WO2003087099A1 (en) | Imidazo-pyridine derivatives as ligands for gaba receptors | |
| JP7805356B2 (ja) | ビヘテロアリール化合物およびその結晶形態を調製するための方法 | |
| WO2003086406A1 (en) | Imidazo-pyridine derivatives as ligands for gaba receptors | |
| CN101558072A (zh) | 吡唑并[3,4-d]嘧啶p38map激酶抑制剂 | |
| US20090036455A1 (en) | Arylpiperazine derivative and use thereof as 5-ht1a receptor ligands |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260216 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260216 |